MA37739A1 - Composés et compositions destinés à la modulation de l'activité de l'egfr - Google Patents

Composés et compositions destinés à la modulation de l'activité de l'egfr

Info

Publication number
MA37739A1
MA37739A1 MA37739A MA37739A MA37739A1 MA 37739 A1 MA37739 A1 MA 37739A1 MA 37739 A MA37739 A MA 37739A MA 37739 A MA37739 A MA 37739A MA 37739 A1 MA37739 A1 MA 37739A1
Authority
MA
Morocco
Prior art keywords
egfr
compounds
activity
modulating
compositions
Prior art date
Application number
MA37739A
Other languages
English (en)
Other versions
MA37739B1 (fr
Inventor
Gerald Lelais
Robert Epple
Marsilje, Iii
Pierre-Yves Michellys
Matthew H Mcneill
Yun Long
Wenshuo Lu
Bei Chen
Badry Bursulaya
Songchun Jiang
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54193706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37739(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of MA37739A1 publication Critical patent/MA37739A1/fr
Publication of MA37739B1 publication Critical patent/MA37739B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des composés et leurs compositions pharmaceutiques, utiles pour la modulation de l'activité de l'egfr, ainsi que des procédés d'utilisation de tels composés pour traiter, améliorer ou prévenir une condition associée à une activité anormale ou dérégulée de l'egfr.
MA37739A 2012-06-06 2013-06-05 Composés et compositions destinés à la modulation de l'activité de l'egfr MA37739B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1741DE2012 2012-06-06
PCT/US2013/044247 WO2013184757A1 (fr) 2012-06-06 2013-06-05 Composés et compositions destinés à la modulation de l'activité de l'egfr

Publications (2)

Publication Number Publication Date
MA37739A1 true MA37739A1 (fr) 2018-09-28
MA37739B1 MA37739B1 (fr) 2018-10-31

Family

ID=54193706

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37739A MA37739B1 (fr) 2012-06-06 2013-06-05 Composés et compositions destinés à la modulation de l'activité de l'egfr

Country Status (42)

Country Link
US (1) US9440957B2 (fr)
EP (2) EP3257848A1 (fr)
JP (1) JP6039800B2 (fr)
KR (1) KR101817829B1 (fr)
CN (1) CN104379575B (fr)
AP (1) AP3909A (fr)
AR (1) AR091368A1 (fr)
AU (1) AU2013271733B2 (fr)
BR (1) BR112014030386B1 (fr)
CA (1) CA2875966C (fr)
CL (1) CL2014003227A1 (fr)
CO (1) CO7160047A2 (fr)
CR (1) CR20140563A (fr)
CU (1) CU20140139A7 (fr)
CY (1) CY1119531T1 (fr)
DK (1) DK2773635T3 (fr)
DO (1) DOP2014000277A (fr)
EA (1) EA026269B1 (fr)
ES (1) ES2645973T3 (fr)
GE (1) GEP201606555B (fr)
GT (1) GT201400282A (fr)
HR (1) HRP20171670T1 (fr)
HU (1) HUE034759T2 (fr)
IL (1) IL235974A (fr)
JO (1) JO3300B1 (fr)
LT (1) LT2773635T (fr)
MA (1) MA37739B1 (fr)
MX (1) MX345630B (fr)
MY (1) MY165036A (fr)
NZ (1) NZ627661A (fr)
PE (1) PE20150726A1 (fr)
PH (1) PH12014502704A1 (fr)
PL (1) PL2773635T3 (fr)
PT (1) PT2773635T (fr)
RS (1) RS56396B1 (fr)
SG (1) SG11201407793TA (fr)
SI (1) SI2773635T1 (fr)
TN (1) TN2014000487A1 (fr)
TW (1) TWI650319B (fr)
UA (1) UA113543C2 (fr)
UY (1) UY34849A (fr)
WO (1) WO2013184757A1 (fr)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037918B1 (ru) 2011-12-21 2021-06-07 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
EP3964513A1 (fr) 2012-04-03 2022-03-09 Novartis AG Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
UA123256C2 (uk) 2012-08-28 2021-03-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Сульфамоїлариламіди та їх застосування як лікарських препаратів для лікування гепатиту b
JP2015526520A (ja) * 2012-08-31 2015-09-10 プリンシピア バイオファーマ インコーポレイテッド Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
ES2640063T3 (es) 2013-04-03 2017-10-31 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
AU2014267235B2 (en) 2013-05-17 2017-10-05 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JP6348978B2 (ja) 2013-07-25 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー グリオキサミド置換ピロールアミド誘導体およびｂ型肝炎を処置するための医薬品としてのその使用
EP3757130A1 (fr) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Méthodes de traitement de cancers hématologiques
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
ES2655518T3 (es) 2013-10-23 2018-02-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
WO2015085482A1 (fr) * 2013-12-10 2015-06-18 Novartis Ag Formes inhibitrices de l'egfr
WO2015081463A1 (fr) * 2013-12-02 2015-06-11 Novartis Ag Formes d'inhibiteurs du recepteur du facteur de croissance epidermique (egfr)
WO2015083059A1 (fr) * 2013-12-02 2015-06-11 Novartis Ag Formes de l'inhibiteur du récepteur du facteur de croissance épidermique (egfr)
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
CN110483484A (zh) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
US9932329B2 (en) 2014-03-03 2018-04-03 Principia Biopharma, Inc. Benzimidazole derivatives as RLK and ITK inhibitors
CU24481B1 (es) 2014-03-14 2020-03-04 Immutep Sas Moléculas de anticuerpo que se unen a lag-3
RU2021101430A (ru) * 2014-03-20 2021-03-16 Капелла Терапьютикс, Инк. Производные бензимидазола как ингибиторы тирозинкиназ erbb для лечения рака
AU2015231215B2 (en) 2014-03-20 2019-07-18 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
WO2015145388A2 (fr) 2014-03-27 2015-10-01 Novartis Ag Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt
AU2015294889B2 (en) * 2014-07-31 2018-03-15 Novartis Ag Combination therapy
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
WO2016055916A1 (fr) 2014-10-06 2016-04-14 Novartis Ag Combinaison thérapeutique pour le traitement du cancer
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
TN2017000375A1 (en) 2015-03-10 2019-01-16 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
WO2016164675A1 (fr) 2015-04-10 2016-10-13 Araxes Pharma Llc Composés quinazoline substitués et leurs procédés d'utilisation
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10881664B2 (en) 2015-05-15 2021-01-05 Novartis Ag Methods for treating EGFR mutant cancers
CN107847448A (zh) * 2015-05-22 2018-03-27 诺华股份有限公司 药物组合物
CA2987914C (fr) 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibiteurs d'egfr et methodes d'utilisation de ceux-ci
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
WO2017019896A1 (fr) 2015-07-29 2017-02-02 Novartis Ag Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
BR112018001640A2 (pt) * 2015-07-29 2018-09-18 Novartis Ag combinação de antagonista da pd-1 com um inibidor de egfr
MX2018002986A (es) * 2015-09-18 2018-05-02 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
WO2017053537A1 (fr) * 2015-09-23 2017-03-30 Capella Therapeutics, Inc. Benzimidazoles pour une utilisation dans le traitement du cancer et des maladies inflammatoires
WO2017058902A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines mutantes kras g12c
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356359B1 (fr) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibiteurs de protéines kras portant la mutation g12c
WO2017058728A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058805A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
EP3356328A1 (fr) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Formes cristallines d'un agent antiviral de l'hépatite b
SG11201803520PA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
JP7015059B2 (ja) 2015-11-16 2022-02-15 アラクセス ファーマ エルエルシー 置換複素環式基を含む２－置換キナゾリン化合物およびその使用方法
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
CA3019628A1 (fr) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Amides heterocycliques utiles en tant que modulateurs de proteine
WO2017175144A1 (fr) 2016-04-08 2017-10-12 Novartis Ag Nouvelles utilisations thérapeutiques
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
US20170321285A1 (en) * 2016-05-03 2017-11-09 The Texas A&M University System Nlrc5 as a biomarker for cancer patients and a target for cancer therapy
WO2018009466A1 (fr) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CN107663170B (zh) * 2016-07-29 2020-02-11 广东东阳光药业有限公司 制备贝西沙星中间体化合物的方法
CA2939286A1 (fr) * 2016-08-17 2018-02-17 Pharmascience Inc. Spirocyclique contenant des composes et usages pharmaceutiques dudit spirocyclique
WO2018064510A1 (fr) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibiteurs de protéines mutantes kras g12c
CN110312711A (zh) 2016-10-07 2019-10-08 亚瑞克西斯制药公司 作为ras抑制剂的杂环化合物及其使用方法
CN110234773B (zh) * 2016-12-13 2024-07-02 匹兹堡大学联邦系统高等教育 治疗含融合基因的癌症的方法
EP3573971A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer
EP3573967A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Composés hétéro-hétéro-bicycliques fusionnés et leurs procédés d'utilisation
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573970A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer
CN106946779A (zh) * 2017-02-13 2017-07-14 广州仁恒医药科技股份有限公司 一种r‑3‑氨基‑六氢氮杂*的制备方法
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3630746A1 (fr) 2017-05-25 2020-04-08 Araxes Pharma LLC Composés et leurs procédés d'utilisation pour le traitement du cancer
JP2020521742A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー Ｋｒａｓの共有結合性阻害剤
WO2018218069A1 (fr) 2017-05-25 2018-11-29 Araxes Pharma Llc Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants
US20190048072A1 (en) 2017-06-22 2019-02-14 Novartis Ag USE OF IL-1beta BINDING ANTIBODIES
SG11201912473PA (en) 2017-06-22 2020-01-30 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018237173A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
WO2018235056A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer
AU2018311522A1 (en) 2017-08-03 2020-01-16 Novartis Ag Therapeutic combination of a third generation EGFR tyrosine kinase inhibitor and a cyclin D kinase inhibitor
MX2020001254A (es) 2017-08-03 2020-03-20 Novartis Ag Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf.
CN109721605B (zh) * 2017-10-31 2022-03-11 维眸生物科技（上海）有限公司 一种免疫细胞迁徙抑制剂
WO2019108900A1 (fr) 2017-11-30 2019-06-06 Novartis Ag Récepteur d'antigène chimérique ciblant le bcma et ses utilisations
JP7313364B2 (ja) * 2018-02-21 2023-07-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｅｇｆｒ阻害剤としての新たなベンズイミダゾール化合物および誘導体
CA3090125A1 (fr) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Schema posologique de modulateur d'assemblage de capside
US20210145842A1 (en) 2018-04-18 2021-05-20 Novartis Ag New therapeutic uses
CR20200503A (es) * 2018-04-26 2020-12-17 Pfizer Inhibidores de cinasa dependientes de ciclina
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
US11492409B2 (en) 2018-06-01 2022-11-08 Novartis Ag Binding molecules against BCMA and uses thereof
WO2020128613A1 (fr) 2018-12-21 2020-06-25 Novartis Ag Utilisation d'anticorps de liaison à il-1bêta
CN109369620B (zh) * 2018-12-22 2020-04-14 山东大学 吡啶类化合物及其制备方法与抗胃癌应用
CN113454077A (zh) 2019-02-22 2021-09-28 爱尔兰詹森科学公司 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
BR112021021454A2 (pt) 2019-05-06 2021-12-21 Janssen Sciences Ireland Unlimited Co Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
EP3986564A1 (fr) * 2019-06-24 2022-04-27 Boehringer Ingelheim International GmbH Nouveaux composés macrocycliques et leurs dérivés utilisés en tant qu'inhibiteurs d'egfr
EP4031578A1 (fr) 2019-09-18 2022-07-27 Novartis AG Anticorps d'entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
EP4045506A4 (fr) * 2019-10-15 2023-08-30 Aucentra Therapeutics Pty Ltd Dérivés de 4-(imidazo[1,2-a] pyridin-3-yl)-n-(pyridin-3-yl)pyrimidin-2-amine pour le traitement de maladies et d'affections prolifératives
KR102267662B1 (ko) * 2019-11-19 2021-06-22 한국화학연구원 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
KR20230008719A (ko) 2020-05-08 2023-01-16 노파르티스 아게 Tno155 및 나자르티닙을 포함하는 약제학적 조합물
EP4154892A4 (fr) * 2020-05-18 2023-12-06 Wellmarker Bio Co., Ltd. Composition pharmaceutique pour la prévention ou le traitement du cancer du poumon à petites cellules associé à des mutants de ron et méthode l'utilisant
EP4154891A4 (fr) * 2020-05-18 2023-12-06 Wellmarker Bio Co., Ltd. Composition pharmaceutique pour la prévention ou le traitement du cancer du poumon non à petites cellules associé à une mutation ron, et méthode l'utilisant
EP4154890A4 (fr) * 2020-05-18 2023-12-06 Wellmarker Bio Co., Ltd. Composition pharmaceutique pour la prévention ou le traitement du cancer du pancréas associé à une mutation ron et méthode l'utilisant
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN113880804A (zh) * 2020-07-01 2022-01-04 微境生物医药科技(上海)有限公司 新型苯并咪唑化合物
AU2021360412A1 (en) * 2020-10-12 2023-06-01 Dana-Farber Cancer Institute, Inc. Covalent egfr inhibitors and methods of use thereof
US12064421B2 (en) 2020-11-02 2024-08-20 Boehringer Ingelheim International Gmbh Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors
WO2022097060A1 (fr) 2020-11-06 2022-05-12 Novartis Ag Molécules de liaison à cd19 et utilisations associées
WO2022242712A1 (fr) * 2021-05-21 2022-11-24 深圳市塔吉瑞生物医药有限公司 Composé macrocyclique substitué, composition comprenant le composé et son utilisation
JP2024523861A (ja) 2021-06-15 2024-07-02 ジェネンテック， インコーポレイテッド がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用
AU2022371404A1 (en) * 2021-10-18 2024-05-23 Dana-Farber Cancer Institute, Inc. Covalent egfr inhibitors and methods of use thereof
KR102572664B1 (ko) * 2022-02-07 2023-08-30 주식회사 인터엠 오디오 클록 조정 및 이를 이용한 네트워크 기반 전관 방송
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2023209090A1 (fr) 2022-04-28 2023-11-02 Astrazeneca Ab Composés hétéroaromatiques bicycliques et leur application dans le traitement du cancer
WO2023209088A1 (fr) 2022-04-28 2023-11-02 Astrazeneca Ab Composés hétéroaromatiques bicycliques et leur utilisation dans le traitement du cancer
WO2023209084A1 (fr) 2022-04-28 2023-11-02 Astrazeneca Ab Composés hétéroaromatiques bicycliques condensés et leur utilisation dans le traitement du cancer
WO2023244587A1 (fr) * 2022-06-14 2023-12-21 Genzyme Corporation Procédés de fabrication de tolébrutinib
TW202416963A (zh) * 2022-09-02 2024-05-01 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｇｆｒ抑制劑及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
CA2350415A1 (fr) 1998-11-18 2000-05-25 Incyte Pharmaceuticals, Inc. Genes associes a des inflammations
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
CA2458533C (fr) 2001-10-09 2011-01-04 Tularik Inc. Derives d'imidazole comme agents anti-inflammatoires
CA2464419A1 (fr) * 2001-11-09 2003-05-22 Boehringer Ingelheim Pharmaceuticals, Inc. Benzimidazoles utilises en tant qu'inhibiteurs de la proteine kinase
US7138420B2 (en) * 2002-08-08 2006-11-21 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzimidazole compounds
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US20080146536A1 (en) 2005-08-16 2008-06-19 Pharmacopeia, Inc. 2-Aminoimidazopyridines for treating neurodegenerative diseases
HUE035029T2 (en) 2008-05-21 2018-03-28 Ariad Pharma Inc Kinase inhibitor phosphorus derivatives
WO2010030857A2 (fr) 2008-09-11 2010-03-18 The Regents Of The University Of Colorado Taux de réponse à une thérapie par des inhibiteurs de l'egfr
US9150577B2 (en) 2009-12-07 2015-10-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
CN102134275B (zh) 2010-01-26 2013-12-04 上海市肿瘤研究所 表皮生长因子受体变异体
WO2011099832A2 (fr) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Nouveau composé de benzimidazole, son procédé de préparation et composition pharmaceutique le contenant
US8221644B2 (en) * 2010-07-20 2012-07-17 Miller Chemical & Fertilizer Corporation Compositions and methods for anti-icing/de-icing
RU2013109143A (ru) 2010-08-05 2014-09-10 Амджен Инк. Бензимидазол- и азабензимидазолсодержащие соединения, которые ингибируют киназу анапластической лимфомы
CA2854936A1 (fr) 2011-11-14 2013-05-23 Tesaro, Inc. Modulation de certaines tyrosine kinases
JP2015526520A (ja) 2012-08-31 2015-09-10 プリンシピア バイオファーマ インコーポレイテッド Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体

Also Published As

Publication number Publication date
EP2773635A1 (fr) 2014-09-10
TN2014000487A1 (en) 2016-03-30
EP2773635B1 (fr) 2017-08-02
BR112014030386A8 (pt) 2021-09-28
BR112014030386A2 (pt) 2017-06-27
ES2645973T3 (es) 2017-12-11
EA201492219A1 (ru) 2015-05-29
UY34849A (es) 2014-01-31
JO3300B1 (ar) 2018-09-16
DOP2014000277A (es) 2015-03-15
NZ627661A (en) 2016-02-26
MX2014014961A (es) 2015-07-17
EA026269B1 (ru) 2017-03-31
PL2773635T3 (pl) 2018-01-31
PH12014502704B1 (en) 2015-02-02
DK2773635T3 (da) 2017-11-06
KR20150023555A (ko) 2015-03-05
AP2014008083A0 (en) 2014-11-30
CN104379575B (zh) 2018-04-17
HRP20171670T1 (hr) 2017-12-15
LT2773635T (lt) 2017-10-10
HUE034759T2 (en) 2018-02-28
UA113543C2 (xx) 2017-02-10
AP3909A (en) 2016-11-24
BR112014030386B1 (pt) 2022-09-27
CL2014003227A1 (es) 2015-02-06
US20150197505A1 (en) 2015-07-16
CO7160047A2 (es) 2015-01-15
GEP201606555B (en) 2016-10-10
IL235974A0 (en) 2015-02-01
CU20140139A7 (es) 2015-04-29
JP6039800B2 (ja) 2016-12-07
AR091368A1 (es) 2015-01-28
PH12014502704A1 (en) 2015-02-02
TWI650319B (zh) 2019-02-11
JP2015518894A (ja) 2015-07-06
MA37739B1 (fr) 2018-10-31
RS56396B1 (sr) 2017-12-29
SG11201407793TA (en) 2014-12-30
MY165036A (en) 2018-02-28
CN104379575A (zh) 2015-02-25
SI2773635T1 (sl) 2017-11-30
EP3257848A1 (fr) 2017-12-20
US9440957B2 (en) 2016-09-13
CR20140563A (es) 2015-01-16
PT2773635T (pt) 2017-09-26
PE20150726A1 (es) 2015-05-17
CA2875966C (fr) 2019-02-26
AU2013271733B2 (en) 2017-02-16
CA2875966A1 (fr) 2013-12-12
IL235974A (en) 2016-11-30
GT201400282A (es) 2015-06-02
TW201350476A (zh) 2013-12-16
KR101817829B1 (ko) 2018-01-11
MX345630B (es) 2017-02-08
CY1119531T1 (el) 2018-03-07
WO2013184757A1 (fr) 2013-12-12
AU2013271733A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
MA37739B1 (fr) Composés et compositions destinés à la modulation de l'activité de l'egfr
MA34948B1 (fr) Composes et procedes de modulation de kinase, et leurs indications
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA44549A1 (fr) Agents immunorègulateurs
MA34969B1 (fr) Composes et compositions en tant qu inibiteurs de trk
MA43186B1 (fr) Anticorps se liant spécifiquement à pd-1 et leurs utilisations
BR112015001613A2 (pt) compostos que são agentes de modulação de s1p e/ou agentes de modulação de atx
BR112018004620A2 (pt) moduladores da expressão de kras
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
MA38341B1 (fr) Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA37538A2 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA38814B2 (fr) Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs
BR112014028991A2 (pt) triazóis como inibidores de kv3
EA201490177A1 (ru) Хиназолины как терапевтические соединения и связанные с ними способы их применения
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
TN2011000669A1 (fr) L-serine pour son utilisation en tant que medicament pour prevenir et/ou traiter une reaction inflammatoire de la peau
MA41988A (fr) Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa
MA38076A1 (fr) Dérivés d'oxazolidin-2-one-pyrimidine
BR112014026160A2 (pt) métodos para tratar intolerância à lactose
GEP20156315B (en) Oxazoline and isoxazoline derivatives as crac modulators
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil